**4. Perspective**

The authors of the perspective, Krist V. Gernaey et al. [21], emphasize that despite the benefits of continuous over-batch bioprocessing, its adoption has lagged, with few exceptions. However, the batch manufacturing paradigm's dominance in the industry for reasons such as "batch processing is familiar and works very well" cannot be sustained in the long term, given the new biomanufacturing challenges. Moreover, the industry-held perception of complexity in continuous bioprocessing is becoming obsolete as more and more new technologies and solutions continually improve the situation. Several academicand industry-led consortia are working to improve the perception regarding continuous bioprocessing by bringing the questions to the correct stakeholders who can address them. The training provided by these initiatives to the top managemen<sup>t</sup> of the companies is playing an essential role in changing the perception and, at the same time, also creating new scientists and operators that can understand and respond to a new set of operational challenges. However, wider adoption of continuous bioprocessing will only be possible if the technical, management, and regulatory gaps are acknowledged. This paper argues that concerted efforts focusing on technology, management, and regulatory aspects are abridging them.

**Funding:** This research received no external funding.

**Acknowledgments:** The authors would like to acknowledge the support of CEPIMA (UPC) Barcelona, Spain.

**Conflicts of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
